$7.00
+0.22 (+3.24%)
Open$6.76
Previous Close$6.78
Day High$7.22
Day Low$6.75
52W High$12.60
52W Low$4.85
Volume—
Avg Volume39.5K
Market Cap27.32M
P/E Ratio0.15
EPS$45.37
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+355.9% upside
Current
$7.00
$7.00
Target
$31.91
$31.91
$24.67
$31.91 avg
$44.05
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.57M | 18.38M | 5.44M |
| Net Income | 187.23M | 471.09M | -1,283,535 |
| Profit Margin | 2,848.6% | 2,706.2% | -23.6% |
| EBITDA | -52,795,958 | -140,218,507 | -2,024,078 |
| Free Cash Flow | — | — | -1,099,827 |
| Rev Growth | -64.2% | -64.2% | +18.0% |
| Debt/Equity | 0.08 | 0.08 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |